

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person <sup>†</sup> <u>Patel Sanj K</u>			2. Issuer Name and Ticker or Trading Symbol <u>Kiniksa Pharmaceuticals International, plc [ KNSA ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>CHAIRMAN &amp; CEO</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>10/20/2025</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<u>23 OLD BOND STREET, THIRD FLOOR</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) <u>LONDON X0 W1S 4PZ</u>								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Ordinary Share	10/20/2025		M <sup>(1)</sup>		121,248	A	\$3.8	233,042	D	
Class A Ordinary Share	10/20/2025		S <sup>(1)</sup>		98,934	D	\$38.81 <sup>(2)</sup>	134,108	D	
Class A Ordinary Share	10/20/2025		S <sup>(1)</sup>		22,314	D	\$39.32 <sup>(3)</sup>	111,794	D	
Class A Ordinary Share	10/21/2025		M <sup>(1)</sup>		39,331	A	\$3.8	151,125	D	
Class A Ordinary Share	10/21/2025		S <sup>(1)</sup>		39,331	D	\$38.77 <sup>(4)</sup>	111,794	D	
Class A Ordinary Share	10/22/2025		M <sup>(1)</sup>		97,390	A	\$3.8	209,184	D	
Class A Ordinary Share	10/22/2025		S <sup>(1)</sup>		97,390	D	\$38.83 <sup>(5)</sup>	111,794	D	
Class A Ordinary Share								109,795	I	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Share Option	\$3.8	10/20/2025		M <sup>(1)</sup>		121,248	(6)	06/28/2027	Class A Ordinary Share	121,248	\$0	136,721	D	
Share Option	\$3.8	10/21/2025		M <sup>(1)</sup>		39,331	(6)	06/28/2027	Class A Ordinary Share	39,331	\$0	97,390	D	
Share Option	\$3.8	10/22/2025		M <sup>(1)</sup>		97,390	(6)	06/28/2027	Class A Ordinary Share	97,390	\$0	0	D	

**Explanation of Responses:**

- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$38.14 and \$39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$39.14 and \$39.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$38.49 and \$39.235. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$38.495 and \$39.255. The price reported in this column reflects a weighted sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option is fully vested and exercisable.

/s/ Douglas Barry, Attorney-in-  
Fact 10/22/2025

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## POWER OF ATTORNEY

With respect to holdings of and transactions in securities issued by Kiniksa Pharmaceuticals International, plc (the “*Company*”), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned’s true and lawful attorney-in-fact to:

1. prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the United States Securities and Exchange Commission (the “*SEC*”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by Kiniksa Pharmaceuticals International, plc, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

---

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of 9/18/2025 .

/s/ Sanj K. Patel

Print Name: Sanj K. Patel

---

**Schedule A**

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

Doug Barry  
Michael Megna  
Mark Ragosa  
Timothy Perdew  
Aaron Young